Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Heart and Blood Diseases

Rare Diseases

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Lymphatic Diseases

Lymphosarcoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Amino Acids

Nivolumab

Trastuzumab

Pertuzumab

Tucatinib

Axitinib

Bosutinib

Olaparib

Ipilimumab

Sirolimus

Palbociclib

Sunitinib

Dasatinib

Crizotinib

Erlotinib Hydrochloride

Temsirolimus

MTOR Inhibitors

Vemurafenib

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Angiogenesis Inhibitors

Growth Inhibitors

Poly(ADP-ribose) Polymerase Inhibitors

Immunosuppressive Agents

Immunologic Factors

Tyrosine

CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL

AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2

* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.
* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

Nivolumab plus Ipilimumab

125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

25mg infused over a 30-60 minute period once a week

Erlotinib

Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.

Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

Trastuzumab plus Pertuzumab

Vemurafenib = 960 mg orally every 12 hours.

Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

Vemurafenib plus Cobimetinib

Vismodegib

Janet Dancey

Quincy Chu

Daniel John Renouf

Francisco Vera-Badillo

Stephen Welch

John Hilton

Lillian Siu

Cristiano Ferrario

Kimberly Hagel

Sunil K. Yadav

Daniel J Renouf

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Recent advances in laboratory technology have enabled the identification of changes in the genetic makeup of tumors that might be responsible for their malignant behavior such as uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be cancer medicines that can specifically act on the tumour's genetic abnormality. Several cancer centers and programs have initiated this type of molecular profiling across Canada, with the goal to identify 'druggable' changes in tumors to find matching therapy for patients. These include initiatives in British Columbia, Ontario and Quebec. The CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of commercially available targeted agents in patients who have undergone tumor profiling and have 'druggable' changes identified in their cancers.

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)	NCT03297606	Lymphoma, Non-H... Multiple Myelom... Advanced Solid ...	Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib	18 Years -	Canadian Cancer Trials Group
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)	NCT03297606	Lymphoma, Non-H... Multiple Myelom... Advanced Solid ...	Olaparib Dasatinib Nivolumab plus ... Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temsirolimus Erlotinib Trastuzumab plu... Vemurafenib plu... Vismodegib Tucatinib	18 Years -	Canadian Cancer Trials Group

Spots Global Cancer Trial Database for vemurafenib plus cobimetinib